New Approach for Cell Therapy Shows Potential Against Solid Tumors with KRAS Mutations
Perelman School of Medicine at the University of PennsylvaniaA new technology for cellular immunotherapy developed by Abramson Cancer Center researchers at Penn Medicine showed promising anti-tumor activity in the lab against hard-to-treat cancers driven by the once-considered “undruggable” KRAS mutation, including lung, colorectal, and pancreatic.